Home Conference Coverage ASH Annual Meeting and Exposition 2021

ASH Annual Meeting and Exposition 2021

Anti-BCMA CAR T-Cell Therapy CT103A Provides Rapid, Durable Responses

Oncology Advanced Practice Providers Face Constraints on Prescribing Authority

Study Suggests Peripheral Blood Cytopenias Represent an Early Marker of Cancer Mortality Risk

Comparing Asciminib With Bosutinib in Patients With Chronic-Phase Chronic Myeloid Leukemia

Final Analysis of the EURO-SKI Study Suggests CML Patients Can Safely Stop TKI Inhibitors

Acalabrutinib Associated With High PFS Benefit in Relapsed/Refractory CLL

Zanubrutinib Plus Venetoclax Well-Tolerated, Effective as First-Line Therapy for CLL/SLL With Del17p

Older Patients With Newly Diagnosed CLL Benefit From Frontline Targeted Treatment

Evaluating Frontline Ibrutinib Plus Venetoclax in Chronic Lymphocytic Leukemia

Study Reviews Response and Survival Outcomes of Transplant for Waldenström Macroglobulinemia

Load more
Subscribe to RSS